Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection

Suzanne E. Ohmit, Frank W. Moler, Arnold S. Monto, Ali S Khan

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Ribavirin was approved in early 1986 for treatment of illness associated with respiratory syncytial virus (RSV) infection in hospitalized children; however, the value of its use remains controversial. This investigation was undertaken to describe ribavirin utilization and to evaluate the effectiveness of ribavirin in reducing the period of hospitalization. All children with laboratory confirmed RSV infection, hospitalized over seven epidemic periods at a single institution, were identified. Characteristics from the medical records of the 768 children and their course of hospitalization were evaluated as determinants of treatment with ribavirin. Very young age as well as diagnoses of congenital heart disease, certain pulmonary conditions, and failure to thrive were all significantly related to increased likelihood of treatment. Children requiring intensive care were likely to be treated; however, the most critically ill children, those who required mechanical ventilation, were not treated. Although these results were in keeping with treatment guidelines for the use of ribavirin, actual utilization declined significantly over the course of the evaluation. The effect of ribavirin treatment on the duration of hospitalization among children with community acquired infection was evaluated in a multivariate model, which controlled for the effects of underlying conditions, measures of illness severity, and epidemic year. This analysis failed to demonstrate a benefit for ribavirin in reducing length of stay; in fact, ribavirin treatment was significantly associated with prolonged hospitalization. It was not likely that the explanation for ribavirin's association with prolonged hospitalization was that the most seriously ill children were treated; however, it was not possible to determine whether this association was due to an adverse effect of treatment or resulted from a perceived need to complete the course of therapy.

Original languageEnglish (US)
Pages (from-to)963-967
Number of pages5
JournalJournal of Clinical Epidemiology
Volume49
Issue number9
DOIs
StatePublished - Jan 1 1996

Fingerprint

Respiratory Syncytial Virus Infections
Hospitalized Child
Ribavirin
Hospitalization
Therapeutics
Community-Acquired Infections
Failure to Thrive
Pulmonary Heart Disease
Critical Care
Artificial Respiration
Critical Illness
Medical Records
Length of Stay
Guidelines

Keywords

  • Antiviral agent
  • Children
  • Clinical effectiveness
  • Hospital duration
  • Infants
  • Respiratory syncytial virus
  • Ribavirin

ASJC Scopus subject areas

  • Epidemiology

Cite this

Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection. / Ohmit, Suzanne E.; Moler, Frank W.; Monto, Arnold S.; Khan, Ali S.

In: Journal of Clinical Epidemiology, Vol. 49, No. 9, 01.01.1996, p. 963-967.

Research output: Contribution to journalArticle

@article{53084abaaf384e548e0f57af5977388c,
title = "Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection",
abstract = "Ribavirin was approved in early 1986 for treatment of illness associated with respiratory syncytial virus (RSV) infection in hospitalized children; however, the value of its use remains controversial. This investigation was undertaken to describe ribavirin utilization and to evaluate the effectiveness of ribavirin in reducing the period of hospitalization. All children with laboratory confirmed RSV infection, hospitalized over seven epidemic periods at a single institution, were identified. Characteristics from the medical records of the 768 children and their course of hospitalization were evaluated as determinants of treatment with ribavirin. Very young age as well as diagnoses of congenital heart disease, certain pulmonary conditions, and failure to thrive were all significantly related to increased likelihood of treatment. Children requiring intensive care were likely to be treated; however, the most critically ill children, those who required mechanical ventilation, were not treated. Although these results were in keeping with treatment guidelines for the use of ribavirin, actual utilization declined significantly over the course of the evaluation. The effect of ribavirin treatment on the duration of hospitalization among children with community acquired infection was evaluated in a multivariate model, which controlled for the effects of underlying conditions, measures of illness severity, and epidemic year. This analysis failed to demonstrate a benefit for ribavirin in reducing length of stay; in fact, ribavirin treatment was significantly associated with prolonged hospitalization. It was not likely that the explanation for ribavirin's association with prolonged hospitalization was that the most seriously ill children were treated; however, it was not possible to determine whether this association was due to an adverse effect of treatment or resulted from a perceived need to complete the course of therapy.",
keywords = "Antiviral agent, Children, Clinical effectiveness, Hospital duration, Infants, Respiratory syncytial virus, Ribavirin",
author = "Ohmit, {Suzanne E.} and Moler, {Frank W.} and Monto, {Arnold S.} and Khan, {Ali S}",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/0895-4356(96)00137-0",
language = "English (US)",
volume = "49",
pages = "963--967",
journal = "Journal of Clinical Epidemiology",
issn = "0895-4356",
publisher = "Elsevier USA",
number = "9",

}

TY - JOUR

T1 - Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection

AU - Ohmit, Suzanne E.

AU - Moler, Frank W.

AU - Monto, Arnold S.

AU - Khan, Ali S

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Ribavirin was approved in early 1986 for treatment of illness associated with respiratory syncytial virus (RSV) infection in hospitalized children; however, the value of its use remains controversial. This investigation was undertaken to describe ribavirin utilization and to evaluate the effectiveness of ribavirin in reducing the period of hospitalization. All children with laboratory confirmed RSV infection, hospitalized over seven epidemic periods at a single institution, were identified. Characteristics from the medical records of the 768 children and their course of hospitalization were evaluated as determinants of treatment with ribavirin. Very young age as well as diagnoses of congenital heart disease, certain pulmonary conditions, and failure to thrive were all significantly related to increased likelihood of treatment. Children requiring intensive care were likely to be treated; however, the most critically ill children, those who required mechanical ventilation, were not treated. Although these results were in keeping with treatment guidelines for the use of ribavirin, actual utilization declined significantly over the course of the evaluation. The effect of ribavirin treatment on the duration of hospitalization among children with community acquired infection was evaluated in a multivariate model, which controlled for the effects of underlying conditions, measures of illness severity, and epidemic year. This analysis failed to demonstrate a benefit for ribavirin in reducing length of stay; in fact, ribavirin treatment was significantly associated with prolonged hospitalization. It was not likely that the explanation for ribavirin's association with prolonged hospitalization was that the most seriously ill children were treated; however, it was not possible to determine whether this association was due to an adverse effect of treatment or resulted from a perceived need to complete the course of therapy.

AB - Ribavirin was approved in early 1986 for treatment of illness associated with respiratory syncytial virus (RSV) infection in hospitalized children; however, the value of its use remains controversial. This investigation was undertaken to describe ribavirin utilization and to evaluate the effectiveness of ribavirin in reducing the period of hospitalization. All children with laboratory confirmed RSV infection, hospitalized over seven epidemic periods at a single institution, were identified. Characteristics from the medical records of the 768 children and their course of hospitalization were evaluated as determinants of treatment with ribavirin. Very young age as well as diagnoses of congenital heart disease, certain pulmonary conditions, and failure to thrive were all significantly related to increased likelihood of treatment. Children requiring intensive care were likely to be treated; however, the most critically ill children, those who required mechanical ventilation, were not treated. Although these results were in keeping with treatment guidelines for the use of ribavirin, actual utilization declined significantly over the course of the evaluation. The effect of ribavirin treatment on the duration of hospitalization among children with community acquired infection was evaluated in a multivariate model, which controlled for the effects of underlying conditions, measures of illness severity, and epidemic year. This analysis failed to demonstrate a benefit for ribavirin in reducing length of stay; in fact, ribavirin treatment was significantly associated with prolonged hospitalization. It was not likely that the explanation for ribavirin's association with prolonged hospitalization was that the most seriously ill children were treated; however, it was not possible to determine whether this association was due to an adverse effect of treatment or resulted from a perceived need to complete the course of therapy.

KW - Antiviral agent

KW - Children

KW - Clinical effectiveness

KW - Hospital duration

KW - Infants

KW - Respiratory syncytial virus

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=0030248129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030248129&partnerID=8YFLogxK

U2 - 10.1016/0895-4356(96)00137-0

DO - 10.1016/0895-4356(96)00137-0

M3 - Article

VL - 49

SP - 963

EP - 967

JO - Journal of Clinical Epidemiology

JF - Journal of Clinical Epidemiology

SN - 0895-4356

IS - 9

ER -